Can-Fite BioPharma Ltd. (TLV:CANF)
Israel · Delayed Price · Currency is ILS · Price in ILA | Market Cap | 17.92M -65.0% |
| Revenue (ttm) | 1.21M -27.7% |
| Net Income | -28.46M |
| EPS | -9.70 |
| Shares Out | 6.06M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 5,740 |
| Open | 303.30 |
| Previous Close | 303.30 |
| Day's Range | 295.50 - 303.30 |
| 52-Week Range | 295.50 - 3,000.00 |
| Beta | -0.02 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 27, 2026 |
About Can-Fite BioPharma
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treat... [Read more]
Financial Performance
In 2025, Can-Fite BioPharma's revenue was $405,000, a decrease of -39.91% compared to the previous year's $674,000. Losses were -$9.83 million, 24.7% more than in 2024.
Financial numbers in USD Financial StatementsNews
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on September 25, 2026, providing details about a securities offering with the SEC.
Can-Fite: Publication Reports Improvement in Decompensated Cirrhosis with Namodenoson and Successful Bridging to Liver Transplantation
Patient Experienced Resolution of Ascites, Regression of Esophageal Varices and Remained Clinically Stable for Approximately 28 Months Prior to Successful Liver Transplantation Ramat Gan, Israel, Sept...
Can-Fite Reports Q2 2026 Financial Results and Ongoing Clinical Progress Highlighting Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
RAMAT GAN, Israel, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma Earnings release: Q2 2026
Can-Fite BioPharma released its Q2 2026 earnings on September 8, 2026, summarizing the period's financial results.
Can-Fite Enters Warrant Exercise Deal For $4 Mln, Shares To Be Issued At Discount; Stock Plunges
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company, on Wednesday announced a definitive agreement for the immediate exercise of certain outstanding warrants to purchase...
CANF Looks 45.6% Undervalued on GF Value™ Despite Challenging Fundamentals
CANF Looks 45.6% Undervalued on GF Value™ Despite Challenging Fundamentals
Can-Fite Announces Exercise of Warrants for Approximately $4.0 Million in Gross Proceeds
RAMAT GAN, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF) (“Can-Fite” or the “Company”), a clinical-stage biotechnology company developing a pipe...
Can-Fite reports longer-than-anticipated survival observed in Namodenoson study
Can-Fite BioPharma (CANF) announced that blinded overall survival observed across the entire patient population in its ongoing pivotal Phase III study of Namodenoson in advanced hepatocellular carcino...
Can-Fite Reports Longer-Than-Anticipated Overall Survival in Ongoing Pivotal Phase III Liver Cancer Study
Company plans to advance the interim analysis of its Phase III Namodenoson study in advanced hepatocellular carcinoma Ramat Gan, Israel, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd.
Can-Fite BioPharma files $100M mixed securities shelf
16:17 EDT Can-Fite BioPharma (CANF) files $100M mixed securities shelf
Can-Fite BioPharma Registration statement: Registration filing
Can-Fite BioPharma filed a registration statement on August 28, 2026, providing details about a securities offering with the SEC.
Can-Fite Releases Positive Data For Namodenoson In Treating Pancreatic Cancer
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company, on Monday announced positive preclinical findings indicating that Namodenoson enhanced the anti-cancer effect of gem...
Can-Fite: Namodenoson Enhances the Anti-Cancer Effect of Chemotherapy in Pancreatic Cancer
The New Mechanistic Findings Support Can-Fite's Ongoing Phase IIb Study Design Following Positive Phase IIa Results Ramat Gan, Israel, Aug. 17, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE ...
Can-Fite Advances Phase III Programs; Namodenoson Retains FDA Fast Track Status
(RTTNews) - Can-Fite BioPharma Ltd. (CANF), a clinical-stage biotechnology company developing small-molecule therapies for oncological and inflammatory diseases, provided an update on the regulatory s...
Can-Fite Highlights Advanced FDA and EMA Regulatory Status of its Phase III Drug Candidates
Namodenoson Holds FDA Fast Track and U.S. and European Orphan Drug Designations; Piclidenoson and Namodenoson Are Advancing in Phase III Programs Ramat Gan, Israel, Aug. 12, 2026 (GLOBE NEWSWIRE) -- C...
Can-Fite submits Piclidenoson clinical study protocol to Bambino Gesu
Can-Fite BioPharma (CANF) announced the submission of a Phase 2 clinical study protocol to Bambino Gesu Children’s Hospital in Rome, Italy, for the first clinical evaluation of Piclidenoson in patient...
Can-Fite Launches First Clinical Program for Piclidenoson in the Rare Genetic Disease Lowe Syndrome
Phase 2 clinical study protocol submitted; Small Phase 2 study designed to support regulatory interactions and potential registration upon positive results Ramat Gan, Israel, Aug. 03, 2026 (GLOBE NEWS...
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology
Predominantly third-line pancreatic cancer patients demonstrated durable survival despite advanced disease; patient who received Namodenoson as second-line therapy remains alive more than 18 months
Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment
Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment
Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson
Can-Fite BioPharma (CANF) announced that the Australian Patent Office has allowed Patent Application No. 2021290439 entitled “Treatment of Advanced Metastatic Cancer.” The patent complements Can-Fite’...
Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer
Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small molec...
Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study
Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study
Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial
Can-Fite BioPharma (CANF) announced completion of enrolment of the first 247 patients in its Phase 3 study evaluating Piclidenoson for the treatment of moderate-to-severe plaque psoriasis. The study h...
Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027
Interim analysis to be conducted under an FDA- and EMA-agreed protocol Ramat Gan, Israel, July 06, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stag...